U.S. patent application number 14/986816 was filed with the patent office on 2016-06-02 for methods for the preparation of hiv attachment inhibitor piperazine prodrug compound.
The applicant listed for this patent is Bristol-Myers Squibb Company. Invention is credited to Michael S. Bultman, Ke Chen, Martin D. Eastgate, Dayne Dustan Fanfair, Richard J. Fox, Thomas E. La Cruz, Boguslaw M. Mudryk, Christina Ann Risatti, James H. Simpson, Maxime C. Soumeillant, Jonathan Clive Tripp, Yi Xiao.
Application Number | 20160152644 14/986816 |
Document ID | / |
Family ID | 47739512 |
Filed Date | 2016-06-02 |
United States Patent
Application |
20160152644 |
Kind Code |
A1 |
Eastgate; Martin D. ; et
al. |
June 2, 2016 |
METHODS FOR THE PREPARATION OF HIV ATTACHMENT INHIBITOR PIPERAZINE
PRODRUG COMPOUND
Abstract
A method for making the compound ##STR00001## is set forth
utilizing the starting material ##STR00002##
Inventors: |
Eastgate; Martin D.;
(Titusville, NJ) ; Bultman; Michael S.;
(Allendale, NJ) ; Chen; Ke; (East Brunswickl,
NJ) ; Fanfair; Dayne Dustan; (East Windsor, NJ)
; Fox; Richard J.; (Yardley, PA) ; La Cruz; Thomas
E.; (North Brunswick, NJ) ; Mudryk; Boguslaw M.;
(East Windsor, NJ) ; Risatti; Christina Ann;
(Princeton, NJ) ; Simpson; James H.;
(Hillsborough, NJ) ; Soumeillant; Maxime C.;
(Hamilton Square, NJ) ; Tripp; Jonathan Clive;
(Foster City, CA) ; Xiao; Yi; (Fanwood,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Bristol-Myers Squibb Company |
Princeton |
NJ |
US |
|
|
Family ID: |
47739512 |
Appl. No.: |
14/986816 |
Filed: |
January 4, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14516664 |
Oct 17, 2014 |
|
|
|
14986816 |
|
|
|
|
13760526 |
Feb 6, 2013 |
8889869 |
|
|
14516664 |
|
|
|
|
61596362 |
Feb 8, 2012 |
|
|
|
Current U.S.
Class: |
544/337 |
Current CPC
Class: |
C07D 207/333 20130101;
C07C 213/08 20130101; C07F 9/098 20130101; C07F 9/650952 20130101;
C07F 9/6561 20130101; C07F 1/02 20130101; C07D 405/04 20130101;
C07D 471/04 20130101 |
International
Class: |
C07F 9/6561 20060101
C07F009/6561; C07C 213/08 20060101 C07C213/08 |
Claims
1. A process for the production of the compound ##STR00072## which
comprises (1) removal of the t-butyl groups from the compound
##STR00073## using a first solvent in the presence of water to
obtain the compound ##STR00074## and (2) reacting the compound
##STR00075## with TRIS and optionally a second solvent to obtain
the compound ##STR00076##
2. The process of claim 1, wherein said first solvent is selected
from the group of NMP, DMSO, MeCN, MeOH, acetone and a carboxylic
acid.
3. and 4. (canceled)
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional application of U.S. Ser.
No. 13/760,526 filed Feb. 6, 2013, now allowed, which claims the
benefit of U.S. Provisional Application Ser. No. 61/596,362 filed
Feb. 8, 2012, which is herein incorporated by reference in its
entirety.
FIELD OF THE INVENTION
[0002] The invention relates to methods of making HIV attachment
inhibitor compounds useful as antivirals, and in particular, to
methods of making the piperazine prodrug compound identified as
1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphon-
ooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine.
The invention also relates to the compounds, including
intermediates, obtained by the processes herein set forth.
BACKGROUND OF THE INVENTION
[0003] HIV-1 (human immunodeficiency virus-1) infection remains a
major medical problem, with tens of millions of people still
infected worldwide at the end of 2011. The number of cases of HIV
and AIDS (acquired immunodeficiency syndrome) has risen rapidly. In
2005, for example, approximately 5.0 million new infections were
reported, and 3.1 million people died from AIDS. Currently
available drugs for the treatment of HIV include nucleoside reverse
transcriptase (RT) inhibitors or approved single pill combinations:
zidovudine (or AZT or RETROVIR.RTM.), didanosine (or VIDEX.RTM.),
stavudine (or ZERIT.RTM.), lamivudine (or 3TC or EPIVIR.RTM.),
zalcitabine (or DDC or HIVID.RTM.), abacavir succinate (or
ZIAGEN.RTM.), Tenofovir disoproxil fumarate salt (or VIREAD.RTM.),
emtricitabine (or FTC or EMTRIVA.RTM.), COMBIVIR.RTM. (contains-3TC
plus AZT), TRIZIVIR.RTM. (contains abacavir, lamivudine, and
zidovudine), EPZICOM.RTM. (contains abacavir and lamivudine),
TRUVADA.RTM. (contains VIREAD.RTM. and EMTRIVA.RTM.);
non-nucleoside reverse transcriptase inhibitors: nevirapine (or
VIRAMUNE.RTM.), delavirdine (or RESCRIPTOR.RTM.) and efavirenz (or
SUSTIVA.RTM.), ATRIPLA.RTM. (TRUVADA.RTM.+SUSTIVA.RTM.), and
etravirine, and peptidomimetic protease inhibitors or approved
formulations: saquinavir, indinavir, ritonavir, nelfinavir,
amprenavir, lopinavir, KALETRA.RTM.(lopinavir and Ritonavir),
darunavir, atazanavir (REYATAZ.RTM.), and tipranavir
(APTIVUS.RTM.), and integrase inhibitors such as raltegravir
(ISENTRESS.RTM.), and entry inhibitors such as enfuvirtide (T-20)
(FUZEON.RTM.) and maraviroc (SELZENTRY.RTM.).
[0004] In addition, HIV attachment inhibitors are a novel subclass
of antiviral compounds that bind to the HIV surface glycoprotein
gp120, and interfere with the interaction between the surface
protein gp120 and the host cell receptor CD4. Thus, they prevent
HIV from attaching to the human CD4 T-cell, and block HIV
replication in the first stage of the HIV life cycle. The
properties of HIV attachment inhibitors have been improved in an
effort to obtain compounds with maximized utility and efficacy as
antiviral agents.
[0005] One HIV attachment inhibitor compound, in particular, has
now shown considerable prowess against HIV. This compound is
identified as
1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl-
)-1H-pyrralo[2,3-c]pyridine-3-yl]-ethane-1,2-dione, and is set
forth and described in U.S. Pat. No. 7,354,924, which is
incorporated herein in its entirety:
##STR00003##
[0006] The above compound is the parent compound of the prodrug
known as
1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphon-
ooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine.
It is set forth and described in U.S. Pat. No. 7,745,625, which is
incorporated by reference herein it its entirety. The compound is
represented by the formula below:
##STR00004##
[0007] Various methods for making this prodrug compound have been
set forth, including those detailed in the '625 reference. In
particular, the '625 reference includes various methods for
acylation, alkylation and phosphorylation. Another patent
reference, U.S. Ser. No. 13/359,708 filed Jan. 27, 2012, entitled
"METHODS OF MAKING HIV ATTACHMENT INHIBITOR PRODRUG COMPOUND AND
INTERMEDIATES", also details various procedures for making the
piperazine prodrug compound. These include a multi-step process
which uses the compound
##STR00005##
as a starting material, which is subsequently brominated, and then
nitrated. Further on, a triazolyl moiety is added to the compound
before further attaching the piperazine moiety separated by dual
carbonyl groups.
[0008] What is now needed in the art are new methods of making the
piperazine prodrug compound which is useful against HIV. These
methods should provide a further comprehensive and efficient means
for making the prodrug molecule, both in terms of overall yield and
material throughput.
SUMMARY OF THE INVENTION
[0009] In a first embodiment, the invention provides a process for
preparing the compound of Formula I
##STR00006##
which comprises: [0010] (a) reacting the compound 1
##STR00007##
[0010] with the acid chloride compound
##STR00008##
to form the compound 2
##STR00009##
and then [0011] (b) contacting the compound 2 with a di-substituted
amine (R.sup.2).sub.2NH in base to produce the compound 3
##STR00010##
[0011] and thereafter [0012] (c) reacting the compound 3 with the
dihydroxy compound
##STR00011##
[0012] in acid solution, wherein the linker between the hydroxyl
groups is C.sub.1-C.sub.6 alkyl, to yield the compound 4
##STR00012##
and [0013] (d) reacting the compound 4 with the compound
##STR00013##
[0013] in acid to produce the compound 5
##STR00014## [0014] (e) contacting the compound 5 with Me-X.sup.4
in base or MeO--R.sup.3 in acid to produce the compound 6
##STR00015##
[0014] and [0015] (f) then performing an oxidation reaction on
compound 6 using [O] to yield the compound 7
##STR00016##
[0015] and [0016] (g) adding the triazolyl group
##STR00017##
[0016] to compound 7, and then conducting a functional group
interconversion reaction, to obtain the compound (I) above,
wherein: [0017] R.sup.2=--H, -Boc, -Piv, --SO.sub.2Aryl,
--CH.sub.2SAryl, --CH.sub.2OP(O)(OR).sub.2, --CH.sub.2OR,
--CH.sub.2Aryl; [0018] R.sup.2.dbd.each independently --H,
--CO.sub.2R, --SO.sub.2Aryl, --CHO; [0019] R.sup.3 and R.sup.4=each
independently --H, --CO.sub.2R, --CH.sub.2SR, --CH.sub.2OR,
--CH(OR).sub.2, --CH(OR)(NR.sub.2), --CH(NR.sub.2).sub.2,
(C.sub.1-C.sub.6) alkyl; [0020] R=each independently --H,
--C.sub.1-C.sub.6 alkyl, -aryl, --CH.sub.2Aryl; [0021]
X.sup.1.dbd.--H, --Cl, --Br, --I,
[0021] ##STR00018## [0022] X.sup.2.dbd.--Cl, --Br, --I,
--N(R.sup.2).sub.2, --OSO.sub.2R; [0023] X.sup.3.dbd.each
independently --H, --OR, --NR.sub.2 --Cl, --Br, --I, --SR,
--SO.sub.2R, --SO.sub.3R, --SR.sub.2.sup.+; [0024] and
X.sup.4.dbd.--Cl, --Br, --I, OTs (tosylate group), +NR.sub.3,
-pyridium, and
##STR00019##
[0024] In this embodiment, it is preferred that R.sup.1 is
--SO.sub.2Aryl. Aryl herein is preferably phenyl. It is also
preferred that X.sup.1 is --H. Additionally, it is preferred that
X.sup.3 is --H. It is also preferred that the dihydroxy compound is
ethylene glycol.
[0025] In a further embodiment, the invention is directed to a
process for preparing the compound of Formula I
##STR00020##
which comprises: [0026] (a) reacting the compound 1
##STR00021##
[0026] with the acid chloride compound
##STR00022##
to to form the compound 2
##STR00023##
and then [0027] (b) contacting the compound 2 with a di-substituted
amine (R.sup.2).sub.2NH in base to produce the compound 3
##STR00024##
[0027] and thereafter [0028] (c) reacting the compound 3 with the
dihydroxy compound
##STR00025##
[0028] in acid solution, wherein the linker between the hydroxyl
groups is C.sub.1-C.sub.6 alkyl, to yield the compound 4
##STR00026##
and [0029] (d) reacting the compound 4 with the compound
##STR00027##
[0029] in acid to produce the compound 5
##STR00028## [0030] (e) contacting the compound 5 with Me-X.sup.4
in base or MeO--R.sup.3 in acid to produce the compound 6
##STR00029##
[0030] and [0031] (f) then performing an oxidation reaction on
compound 6 using [O] to yield the compound
##STR00030##
[0031] and [0032] (g) adding the triazolyl group 9
##STR00031##
[0032] to compound 7, to obtain the compound (I) above wherein:
[0033] R.sup.1.dbd.--H, -Boc, -Piv, --SO.sub.2Aryl,
--CH.sub.2SAryl, --CH.sub.2OP(O)(OR).sub.2, --CH.sub.2OR,
--CH.sub.2Aryl; [0034] R.sup.2=each independently --H, --CO.sub.2R,
--SO.sub.2Aryl, --CHO; [0035] R.sup.3.dbd.--H, --CO.sub.2R,
--CH.sub.2SR, --CH.sub.2OR, --CH(OR).sub.2, --CH(OR)(NR.sub.2),
--CH(NR.sub.2).sub.2; [0036] R =each independently --H,
--C.sub.1-C.sub.6 alkyl, -aryl, --CH.sub.2Aryl; [0037]
X.sup.1.dbd.--H, --Cl, --Br, --I,
[0037] ##STR00032## [0038] X.sup.2.dbd.--Cl, --Br, --I,
--N(R.sup.2).sub.2, --OSO.sub.2R; [0039] X.sup.3=each independently
--H, --OR, --NR.sub.2, Cl, --Br, --I, --SR, --SO.sub.2R,
--SO.sub.3R, --SR.sub.2.sup.+; [0040] and X.sup.4.dbd.--Cl, --Br,
--I, --OTs, +NR.sub.3, -pyridium, and
##STR00033##
[0040] In this further embodiment, it is preferred that R.sup.1 is
--SO.sub.2Aryl. Aryl herein is preferably phenyl. It is also
preferred that X.sup.1 is --H. Additionally, it is preferred that
X.sup.3 is --H. It is also preferred that the dihydroxy compound is
ethylene glycol.
[0041] In another embodiment, there is provided a process for the
preparation of the compound of Formula I
##STR00034##
which comprises: [0042] (a) reacting the compound 1
##STR00035##
[0042] with the acid chloride compound
##STR00036##
to form the compound 2
##STR00037##
and then [0043] (b) contacting the compound 2 with a di-substituted
amine (R.sup.2).sub.2NH in base to produce the compound 3
##STR00038##
[0043] and thereafter [0044] (c) reacting the compound 3 with the
dihydroxy compound
##STR00039##
[0044] in acid solution, wherein the linker between the hydroxyl
groups is C.sub.1-C.sub.6 alkyl, to yield the compound 4
##STR00040##
and [0045] (d) reacting the compound 4 with the compound
##STR00041##
[0045] in acid to produce the compound 5
##STR00042## [0046] (e) contacting the compound 5 with Me-X.sup.4
in base or MeO--R.sup.3 in acid to produce the compound 6
##STR00043##
[0046] and then [0047] (f) performing an oxidation reaction on
compound 6 using [O] to yield the compound 7
##STR00044##
[0047] and [0048] (g) performing an activation reaction to yield
the resultant compound 10
##STR00045##
[0048] and then [0049] (h) adding the triazolyl group 9
##STR00046##
[0049] to compound 10 in the presence of Cu ion and a ligand to
yield the compound of Formula (I) above wherein: [0050]
R.sup.1.dbd.--H, -Boc, -Piv, --SO.sub.2Aryl, --CH.sub.2SAryl,
--CH.sub.2OP(O)(OR).sub.2, --CH.sub.2OR, --CH.sub.2Aryl; [0051]
R.sup.2=each independently --H, --CO.sub.2R, --SO.sub.2Aryl, --CHO;
[0052] R.sup.3.dbd.--H, --CO.sub.2R, --CH.sub.2SR, --CH.sub.2OR,
--CH(OR).sub.2, --CH(OR)(NR.sub.2), --CH(NR.sub.2).sub.2; [0053]
R=each independently --H, --C.sub.1-C.sub.6 alkyl, -aryl,
--CH.sub.2Aryl; [0054] X.sup.1.dbd.--H, --Cl, --Br, --I,
[0054] ##STR00047## [0055] X.sup.2.dbd.--Cl, --Br, --I,
--N(R.sup.2).sub.2, --OSO.sub.2R; [0056] X.sup.3and X.sup.5=each
independently --H, --OR, --NR.sub.2, --Cl, --Br, --I, --SR,
--SO.sub.2R, --SO.sub.3R, --SR.sub.2.sup.+; [0057] and
X.sup.4.dbd.--Cl, --Br, --I, --OTs, +NR.sub.3, pyridium, and
##STR00048##
[0057] The ligand is selected from the group of
1,2-diaminocyclohexane, trans-1,2-diaminocyclohexane,
cis-/trans-diaminocyclohexane,
cis-N,N'-dimethyl-1,2-diaminocyclohexane,
trans-N,N'-dimethyl-1,2-diaminocyclohexane,
cis-/trans-N,N'-dimethyl-1,2-diaminocyclohexane, 1,2-diaminoethane,
N,N'-dimethyl-1,2-diaminoethane, 1,10-phenanthroline,
4,7-diphenyl-1,10-phenantroline, 5-methyl-1,10-phenanthroline,
5-chloro-1,10-phenantroline, and 5-nitro-1,10-phenanthroline. In
this further embodiment, it is preferred that R.sup.1 is
--SO.sub.2Aryl. Aryl herein is preferably phenyl. It is also
preferred that X.sup.1 is --H. Additionally, it is preferred that
X.sup.3 is --H.
[0058] Also provided herein is a method of making the compound of
Formula II
##STR00049##
which comprises: [0059] (a) acylating the compound 10
##STR00050##
[0059] using
##STR00051##
to yield the compound 11
##STR00052##
and then [0060] (b) reacting compound 11 with compound 13
##STR00053##
[0060] in an activation reaction to produce compound 14
##STR00054##
and [0061] (c) adding the triazolyl compound 9
##STR00055##
[0061] in the presence of Cu ion and a ligand to obtain compound
15
##STR00056##
and [0062] (d) reacting compound 17
##STR00057##
[0062] with compound 15 to produce compound 18
##STR00058##
and [0063] (e) conducting a functional group interconversion
reaction to yield the compound of Formula II above; wherein: [0064]
R.sup.5.dbd.--H, --OR, --NR.sub.2, --Cl, --Br, --I, --SR; [0065]
R.sup.6.dbd.--H, -Boc, -Piv, --SO.sub.2Aryl, --CH.sub.2SAryl,
CH.sub.2OP(O)(OR).sub.2, --CH.sub.2OR, --CH.sub.2Aryl, --Li, --Na,
--K, --Ca, --Mg, TMG (Tetramethyl guanidine); [0066] R=each
independently --H, --C.sub.1-C.sub.6 alkyl, -aryl, --CH.sub.2Aryl;
[0067] X.sup.1.dbd.--H, --Cl, --Br, --I,
[0067] ##STR00059## [0068] X.sup.5.dbd.--H, --OR, --NR.sub.2, --Cl,
--Br, --I, --SR [0069] X.sup.6.dbd.--H, --OR, --NR.sub.2, --Cl,
--Br, --I, --SR, --SO.sub.2R, --SR.sub.2.sup.+, --OSO.sub.2R,
--OSO.sub.3R; [0070] and X.sup.7.dbd.--Cl, --Br, --I, --OSO.sub.2R.
In this embodiment, the ligand may be selected as previously set
forth. It is also preferred that R=tert-butyl, R.sup.6 and X.sup.1
are --H, and R.sup.5 is --OMe. Aryl herein is preferably
phenyl.
[0071] For a further embodiment of the invention, there is set
forth process for making the compound of Formula III
##STR00060##
which comprises: [0072] (1) reacting compound
##STR00061##
[0072] with phthalic anhydride, H.sub.2O.sub.2 and dichloromethane
to yield compound
##STR00062##
and [0073] (2) conducting a PyBrop bromination reaction by reacting
compound ii with PyBrop to prepare compound III,
[0073] ##STR00063## [0074] wherein R.sup.7.dbd.--H, alkyl, aryl,
--SO.sub.2R, --C(O)OR, and --C(O)NR.sub.2; and [0075] wherein
R.dbd.--H, --C.sub.1-C.sub.6 alkyl, aryl, --CH.sub.2Aryl; and
further wherein PyBrop is the peptide coupling reagent
Bromo-tris-pyrrolidino phosphoniumhexafluorophosphate. Aryl herein
is preferably phenyl.
[0076] In addition, the invention is also directed to a compound,
including pharmaceutically acceptable salts and mixtures thereof,
which is selected from the group of:
##STR00064##
[0077] The invention also is directed to a process for the
production of the compound
##STR00065##
which comprises [0078] (1) removal of the t-butyl groups from the
compound
##STR00066##
[0078] using a solvent in the presence of water to obtain the
compound
##STR00067##
and [0079] (2) reacting the compound
##STR00068##
[0079] with TRIS (tris(hydroxymethyl)aminomethane) and optionally a
second solvent to obtain the compound
##STR00069##
[0080] According to this process, the first solvent is selected
from the group of carboxylic acid, NMP (N-methyl-2-pyrrolidone),
DMSO, MeCN, MeOH, and acetone. The acid is selected from the group
of H.sub.2SO.sub.4, HNO.sub.3, HCl, phosphoric and carboxylic
acids. The second solvent is selected from the group of water,
alkyl ketone, heptane, toluene, ethyl acetate, DMSO, MeCN, MeOH and
acetone. Even more preferably, the acid is acetic acid, and the
second solvent is acetone.
[0081] The present invention is directed to these, as well as other
important ends, hereinafter described.
DETAILED DESCRIPTION OF THE EMBODIMENTS
[0082] Unless otherwise specifically set forth, many reagents have
been identified herein by their commonly accepted letter
abbreviations in the art for ease of reference.
[0083] In addition, unless otherwise specifically set forth
elsewhere in the application, the following terms may be used
herein, and shall have the following meanings:
[0084] An "alkyl" group refers to a saturated aliphatic hydrocarbon
including straight chain and branched chain groups. Preferably, the
alkyl group has 1 to 20 carbon atoms (whenever a numerical range;
e.g., "1-20", is stated herein, it means that the group, in this
case the alkyl group may contain 1 carbon atom, 2 carbon atoms, 3
carbon atoms, etc. up to and including 20 carbon atoms). More
preferably, it is a medium size alkyl having 1 to 10 carbon atoms.
Most preferably, it is a lower alkyl having 1 to 4 carbon atoms.
The alkyl group may be substituted or unsubstituted.
[0085] The term "C.sub.1-6 alkyl" as used herein and in the claims
means straight or branched chain alkyl groups with up to and
including 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, t-butyl, amyl, hexyl and the like.
[0086] An "aryl" "Aryl" or "Ar" group refers to an all carbon
monocyclic or fused-ring polycyclic(i.e., rings which share
adjacent pairs of carbon atoms) groups having a completely
conjugated pi-electron system. Examples, without limitation, of
aryl groups are phenyl, napthalenyl and anthracenyl. The aryl group
may be substituted or unsubstituted.
[0087] In a preferred embodiment of the invention, the synthesis of
the piperazine prodrug compound can be set forth in the following
flow diagram:
##STR00070##
[0088] Even more preferably, as further set forth below, the
synthesis of the piperazine prodrug compound begins from the
N-sulfonylated pyrrole 1a. Friedel-Crafts acylation with 2-chloro
acetyl chloride, in the presence of aluminum trichloride, provides
the 3-acryl pyrrole derivative 2a. Displacement of the 2-choro
ketone by the sodium salt of the N-formyl sulfonamide, in the
presence of a tetraalkylammonium halide, preferably bromide,
preferably tetrabutylammonium bromide, provides the amino-ketone
3a. Ketal protection of the ketone, in the presence of glycol and
acid, results in the cleavage of the N-formyl protecting group and
formation of the desired dioxalane 4a. A Pictet-Spengler
cyclization with a formaldehyde equivalent, catalyzed by acid,
provides the ketone 5a, which is treated with trimethyl
orthoformate (TMOF) and acid in the presence of a radical initiator
such as AlBN or cumene hydroperoxide to give the 6-azaindole 6a.
Oxidation of the pyridine nitrogen provides the N-oxide 7a which is
then treated with PyBrop in the presence of base, which brominates
the C7-position, yielding the bromo-azaindole 8a after hydrolysis
of the sulfonyl protecting group. A second Friedel-Crafts acylation
onto C3 of the indole provides the oxalate 9a, which is coupled
with the N-benzoyl piperazine to give the amide 10a. Addition of
the triazole is catalyzed by copper, in the presence of an
appropriate ligand and base, to give the indole 11c which is
isolated as its lithium salt (or optionally as a co-salt with KBr).
Alkylation of the indole nitrogen with the chloro-phosphate 14a
gives the phosphate ester 12a, and subsequent solvolysis of the
tert-butyl groups provides the final compound 13a.
[0089] Thus, the production of the piperazine prodrug compound may
be shown more precisely as follows:
##STR00071##
[0090] The foregoing description is merely illustrative and should
not be understood to limit the scope or underlying principles of
the invention in any way. Indeed, various modifications of the
invention, in addition to those shown and described herein, will
become apparent to those skilled in the art from the foregoing
description and examples. Such modifications are also intended to
fall within the scope of the appended claims.
* * * * *